Phase I/II clinical trial: Immunotherapy of prostate cancer patients in biochemical relapse with dendritic cell-based vaccine

Trial Profile

Phase I/II clinical trial: Immunotherapy of prostate cancer patients in biochemical relapse with dendritic cell-based vaccine

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Stapuldencel-T (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jun 2014 The status has been changed from recruiting to discontinued according to the European Clinical Trials database.
    • 29 May 2014 According to a SOTIO media release, results from this trial will be presented at the 2014 American Society of Clinical Oncology Annual Meeting.
    • 29 Mar 2012 Planned number of patients changed from 15 to 30 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top